25 June 2025

Serious Safety Concerns Regarding the Use of Melanotan II (Barbie Drug)

Reference: CIR-2025-00000111

Serious Safety Concerns Regarding the Use of Melanotan II (Barbie Drug)

To all Health facilities and healthcare practitioners in Dubai's private health sector

 

Referring to the above subject, DHA notifies all health facilities regarding the circulars issued by the MOHAP for perusal and adherence to what is stated.

Circular No. 06  for the year 2025 Serious Safety Concerns Regarding the Use of Melanotan II (Barbie Drug)

 

Thanks in advance for your good co-operation

 

Drug Control Section

Health Regulation Sector

DHA